ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformation

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

Efficacy and safety of glofitamab for patients with Richter’s transformationПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Glofitamab for Richter’s TransformationПодробнее

New DLBCL Clinical Trial: Epcoritamab for Diffuse Large B-Cell LymphomaПодробнее

BRUIN: pirtobrutinib shows efficacy for Richter's transformationПодробнее

Early results from EPCORE CLL-1 trial: subcutaneous epcoritamab in patients with Richter’s syndromeПодробнее

Promising agents emerging for Richter’s transformationПодробнее

Promising therapies for Richter's transformation: ven-R-CHOP, epcoritamab, pirtobrutinib & CAR-TПодробнее

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumabПодробнее

Subcutaneous Epcoritamab for Richter's Syndrome - Dr. Arnon Kater ASH 2022Подробнее

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell LymphomaПодробнее

The current SoC in Richter’s transformation and the potential role of CAR T-cell therapyПодробнее

CD20/CD3 bispecific antibodies in R/R DLBCL: glofitamab and epcoritamabПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCLПодробнее

Venetoclax, Obinutuzumab, and Atezolizumab for Richter's Transformation - Dr. Nitin Jain ASH 2021Подробнее

Epcoritamab monotherapy and combinations in R/R CLL and Richter’s syndromeПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCLПодробнее